Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy

  • Shulin Wu
  • Sharron X. Lin
  • Min Lu
  • Alexander O. Subtelny
  • Zongwei Wang
  • Douglas M. Dahl
  • Aria F. Olumi
  • Chin-Lee WuEmail author
Urology - Original Paper



To investigate the oncological impact of incidental prostate cancer (iPCa) found during radical cystoprostatectomy (RCP) on overall survival (OS) prognosis of urothelial carcinoma of the bladder (BCa).

Patients and methods

A total of 122 RCP cases resected between 2002 and 2012 at our center were included for study. Survival of BCa patient was compared using the Kaplan–Meier method and the log-rank test. Cox proportional hazards regression models were used to analyze the impact of iPCa on the 5-year overall mortality of BCa patients after RCP.


Among the 122 BCa cases that underwent RCP, 38 cases (31.1%) had iPCa, in which, 17 cases (44.7%) were identified as clinically significant iPCa (csPCa). BCa patients with iPCa were older (71 vs 64 years, p = 0.004) and had higher preoperative PSA level (3.1 ng/mL vs 1.4 ng/mL, p = 0.017) when compared to those without iPCa. Cases with iPCa showed a more favorable 5-year OS than cases without iPCa, although this difference did not reach statistical significance (p = 0.219). When excluding the higher risk cases with Gleason score (GS) ≥ 4 + 3 and/or preoperative PSA > 10 ng/mL, BCa patients with iPCa showed a significantly longer OS than cases without iPCa on univariate analysis (p = 0.044), but not on multivariate analysis (p = 0.125).


Our results demonstrated that the frequent findings of low-risk iPCa in BCa patients could indicate the potential possibility of shared pathogenesis pathways between iPCa and BCa. Future study with a larger cohort is warranted to validate this result.


Bladder cancer Incidental prostate cancer Cystoprostatectomy Prognosis Androgen receptor 



Urothelial carcinoma of the bladder


Muscle-invasive bladder cancer






Incidental prostate cancer


Clinical significant iPCa


Clinical insignificant iPCa


Prostate-specific antigen


Digital rectal examination


Gleason score


Lymphovascular invasion


Perineural invasion


Soft-tissue surgical margin


Androgen receptor


Androgen deprivation therapy


Interquartile range


Compliance with ethical standards

Conflict of interest

All the authors declare that there is no conflict of interest.

Ethical approval

All procedures involving human participants were performed in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and subsequent amendments or comparable ethical standards.


  1. 1.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66(1):7–30. PubMedGoogle Scholar
  2. 2.
    Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder C (2013) ICUD-EAU International consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1):45–57. PubMedGoogle Scholar
  3. 3.
    Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G (2017) Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: a systematic review and meta-analysis of 13,140 patients. J Urol 197(2):385–390. PubMedGoogle Scholar
  4. 4.
    Wolters T, Montironi R, Mazzucchelli R, Scarpelli M, Roobol MJ, van den Bergh RC, van Leeuwen PJ, Hoedemaeker RF, van Leenders GJ, Schroder FH, van der Kwast TH (2012) Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate 72(1):108–115. PubMedGoogle Scholar
  5. 5.
    Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M, Raspollini MR, Montironi R (2017) Concomitant bladder cancer and prostate cancer: challenges and controversies. Nat Rev Urol 14(10):620–629. PubMedGoogle Scholar
  6. 6.
    Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368–374PubMedGoogle Scholar
  7. 7.
    Buse S, Hofner T, Muller SC, Hermann E, Wieland WF, May M, Stief CG, Bastian PJ, Hohenfellner M, Haferkamp A (2013) Characterization and risk stratification of prostate cancer in patients undergoing radical cystoprostatectomy. Int J Urol 20(9):866–871. PubMedGoogle Scholar
  8. 8.
    Thomas C, Giesswein A, Hainz M, Stein R, Rubenwolf P, Roos FC, Neisius A, Nestler S, Hampel C, Jager W, Wiesner C, Thuroff JW (2015) Concomitant Gleason Score %3e/= 7 prostate cancer is an independent prognosticator for poor survival in nonmetastatic bladder cancer patients undergoing radical cystoprostatectomy. Int Urol Nephrol 47(11):1789–1796. PubMedGoogle Scholar
  9. 9.
    Gakis G, Rink M, Fritsche HM, Graefen M, Schubert T, Hassan F, Chun FK, Brummeisl W, Fisch M, Burger M, Stenzl A, Renninger M (2016) Prognostic significance of incidental prostate cancer at radical cystoprostatectomy for bladder cancer. Urol Int 97(1):42–48. PubMedGoogle Scholar
  10. 10.
    Sruogis A, Ulys A, Smailyte G, Kardelis Z, Kulboka A, Anglickiene G, Samalavicius N, Anglickis M (2012) Incidentally found prostate cancer and influence on overall survival after radical cystoprostatectomy. Prostate Cancer 2012:690210. PubMedGoogle Scholar
  11. 11.
    Malte R, Kluth LA, Kaushik D, Boorjian SA, Abufaraj M, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz PI, Roupret M, Briganti A, Scherr DS, Shariat SF, Seebacher V (2017) Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. Eur J Surg Oncol 43(11):2193–2199. PubMedGoogle Scholar
  12. 12.
    Kaelberer JB, O'Donnell MA, Mitchell DL, Snow AN, Mott SL, Buatti JM, Smith MC, Watkins JM (2016) Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival. Prostate Int 4(3):107–112. PubMedGoogle Scholar
  13. 13.
    Cho IC, Kim JE, Kim SH, Joung JY, Seo HK, Chung J, Park WS, Lee KH (2015) Oncologic aspects of long-term followed incidental prostate cancer detected by cystoprostatectomy in Korean patients. Prostate Int 3(2):56–61. PubMedGoogle Scholar
  14. 14.
    Pan J, Xue W, Sha J, Yang H, Xu F, Xuan H, Li D, Huang Y (2014) Incidental prostate cancer at the time of cystectomy: the incidence and clinicopathological features in Chinese patients. PLoS ONE 9(4):e94490. PubMedGoogle Scholar
  15. 15.
    Moschini M, Shariat SF, Freschi M, Soria F, Abufaraj M, Gandaglia G, Dell'Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R (2017) Impact of prostate involvement on outcomes in patients treated with radical cystoprostatectomy for bladder cancer. Urol Int 98(3):290–297. PubMedGoogle Scholar
  16. 16.
    Singh A, Kinoshita Y, Rovito PM Jr, Landas S, Silberstein J, Nsouli I, Wang CY, Haas GP (2008) Higher than expected association of clinical prostate and bladder cancers. J Urol 179(5 Suppl):S2–5. PubMedGoogle Scholar
  17. 17.
    Gakis G, Stenzl A, Renninger M (2013) Evolution of the concept of androgen-sensitive bladder cancer. Scand J Urol 47(3):173–178. PubMedGoogle Scholar
  18. 18.
    Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y, Zhu X, Olumi AF, Zhong WD, Wu CL (2018) Expression of aromatase in tumor related stroma is associated with human bladder cancer progression. Cancer Biol Ther 19(3):175–180. PubMedGoogle Scholar
  19. 19.
    Chen CC, Huang CP, Tsai YT, Hseih TF, Shyr CR (2017) The genomic alterations of 5alpha-reductases and their inhibitor finasteride's effect in bladder cancer. Anticancer Res 37(12):6893–6898. PubMedGoogle Scholar
  20. 20.
    Shiota M, Kiyoshima K, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J, Tatsugami K, Eto M (2017) Suppressed recurrent bladder cancer after androgen suppression with androgen deprivation therapy or 5alpha-reductase inhibitor. J Urol 197(2):308–313. PubMedGoogle Scholar
  21. 21.
    Morales EE, Grill S, Svatek RS, Kaushik D, Thompson IM Jr, Ankerst DP, Liss MA (2016) Finasteride reduces risk of bladder cancer in a large prospective screening study. Eur Urol 69(3):407–410. PubMedGoogle Scholar
  22. 22.
    Izumi K, Taguri M, Miyamoto H, Hara Y, Kishida T, Chiba K, Murai T, Hirai K, Suzuki K, Fujinami K, Ueki T, Udagawa K, Kitami K, Moriyama M, Miyoshi Y, Tsuchiya F, Ikeda I, Kobayashi K, Sato M, Morita S, Noguchi K, Uemura H (2014) Androgen deprivation therapy prevents bladder cancer recurrence. Oncotarget 5(24):12665–12674. PubMedGoogle Scholar
  23. 23.
    Makela VJ, Kotsar A, Tammela TL, Murtola TJ (2018) Bladder cancer survival in men using 5-alpha-reductase inhibitors. J Urol. PubMedGoogle Scholar
  24. 24.
    Taylor JA 3rd, Kuchel GA (2009) Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6(3):135–144. PubMedGoogle Scholar
  25. 25.
    D'Amico AV (2011) Risk-based management of prostate cancer. N Engl J Med 365(2):169–171. PubMedGoogle Scholar
  26. 26.
    Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 99(7):558–568. PubMedGoogle Scholar
  27. 27.
    Chang C, Lee SO, Yeh S, Chang TM (2014) Androgen receptor (AR) differential roles in hormone-related tumors including prostate, bladder, kidney, lung, breast and liver. Oncogene 33(25):3225–3234. PubMedGoogle Scholar
  28. 28.
    Kinoshita Y, Singh A, Rovito PM Jr, Wang CY, Haas GP (2004) Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer 3(2):83–86PubMedGoogle Scholar
  29. 29.
    Chun TY (1997) Coincidence of bladder and prostate cancer. J Urol 157(1):65–67PubMedGoogle Scholar
  30. 30.
    Vallancien G, Abou El Fettouh H, Cathelineau X, Baumert H, Fromont G, Guillonneau B (2002) Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 168(6):2413–2417. PubMedGoogle Scholar
  31. 31.
    Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol 71(6):952–960. PubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Urology and Pathology, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Department of PathologyPeking University Health Science CenterBeijingChina
  3. 3.Division of Urologic Surgery, Beth Israel Deaconess Medical CenterHarvard Medical SchoolBostonUSA

Personalised recommendations